Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Lakefront Appoints Eric Hedrick, MD, as Chief Medical Officer
Mechelen, Belgium**; June 8, 2026, 22:01 CET; Lakefront Bio****therapeutics NV (Euronext & NASDAQ: LKFT) today announced that Eric Hedrick, MD has been appointed Chief Medical Officer. This expanded leadership role supports the Company’s strategic transformation following its acquisition of Ouro Medicines operational assets announced on June 4, 2026.**1 Eric will report to Henry Gosebruch, CEO and join the Company’s Management Committee.
“Eric has been an invaluable contributor over this past year, driving our clinical assessments and partnering with our external colleagues,” said Henry Gosebruch, Chief Executive Officer of Lakefront. “The Ouro portfolio is now the cornerstone of Lakefront’s R&D pipeline and I’m thrilled to have a talented drug developer of Eric’s caliber and experience to guide the development of gamgertamig and our future clinical programs.”
Dr. Hedrick has a twenty-five year track record successfully developing effective and commercially successful therapies in the pharmaceutical and biotechnology industry. Prior to joining Lakefront in July, 2025 to serve as clinical evaluation lead for new pipeline opportunities, Dr. Hedrick held roles as Chief Executive Physician at EQRx, Chief Advisor and Interim Chief Medical Officer for BeiGene, Chief Medical Officer at Epizyme and Interim Chief Medical Officer at Pharmacyclics. Dr. Hedrick started his career in biotechnology at Genentech. He received his M.D. from the University of Maryland and was previously an attending physician at the Memorial Sloan-Kettering Cancer Center.
About Lakefront****® Biotherapeutics
Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company built to bring meaningful medicines to patients with serious diseases in therapeutic areas of unmet need. The Company combines world-class deal making expertise with capital to identify, acquire, and advance promising opportunities that have the potential to drive value for patients and shareholders. Applying a modality-agnostic asset selection approach and operational flexibility, Lakefront Biotherapeutics prioritizes oncology and immunology & inflammation programs with clear clinical proof-of-concept in emerging areas. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.
Investor Relations
Sherri Spear +1 412 522 6418